[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"seminoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:seminoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,44,75,97,122,144,169,207,236],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100639887","pristine-trial-proton-beam-therapy-in-seminoma---toxicity-investigation-and-evaluation-of-outcome-100639887",false,"NCT07601672","PRISTINE Trial: PRoton Beam Therapy In Seminoma - Toxicity INvestigation and Evaluation of Outcome","PRISTINE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Male gender\n* ECOG Performance status 0 - 1\n* Histologically confirmed diagnosis of testicular seminoma\n* Stage IIA - IIB disease with metastatic involvement limited to retroperitoneal lymph nodes measuring ≤3 cm in greatest diameter\n* Prior radical orchiectomy\n* Clinical indication for radiotherapy\n* Written informed consent provided\n\nExclusion Criteria:\n\n* Non-seminomatous germ cell tumor histology\n* Incomplete definitive surgical orchiectomy, including diagnostic biopsy alone\n* Prior or concurrent second malignancy other than non-melanoma skin cancer, unless disease free for a minimum of five years\n* Prior radiotherapy to the abdominal or pelvic region\n* Known severe, active co-morbidity\n* Inability or refusal to provide informed consent","MALE","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","Stage II seminoma is a type of cancer that is usually highly curable and most often affects young men.\n\nRadiotherapy is an effective treatment, but it can sometimes cause side effects in the long term and, rarely, increase the risk of developing another cancer later in life.For this reason, more targeted treatments are being explored, such as proton therapy (PBT). This type of radiotherapy uses protons to better focus the treatment on the tumor while reducing exposure to the surrounding healthy tissues.The goal is to treat the cancer effectively while minimizing side effects as much as possible.",[26],"Seminoma",[28,29,30,31],"seminoma","cancer treatment","protontherapy","radiotherapy","NOT_YET_RECRUITING","2026-05-15",{"date":35,"type":36},"2026-05-22","ACTUAL",{"date":38,"type":20},"2026-05-01",{"date":40,"type":20},"2031-05-01",{"name":42,"class":43},"Istituto Clinico Humanitas","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100631306","primary-rplnd-versus-systemic-chemotherapy-in-good-prognosis-metastatic-testicular-cancer-100631306","NCT07498959","Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer","Testicular Cancer Treatment: Assessing Quality of Life in Good Prognosis Metastastic Disease","TESTIGO","Inclusion Criteria:\n\n* Patients ≥18 years undergoing an open or minimally invasive primary retroperitoneal lymph node dissection (RPLND) due to seminoma stage II A\u002FB (maximum 2 nodes, \\\u003C30 mm in any dimension)\n* Patients undergoing an open or minimally invasive primary RPLND due to a retroperitoneal relapse of seminoma (maximum 2 nodes, \\\u003C30 mm in any dimension)\n* Patients ≥18 years scheduled for 3-4 courses of chemotherapy due to a newly diagnosed good-prognosis metastatic germ cell tumor (nonseminoma or seminoma)\n\nExclusion Criteria:\n\n* Previous chemotherapy (including adjuvant chemotherapy at diagnosis)\n* Previous RPLND\n* Practical considerations, such as not being able to read and sign informed consent or understand the questionnaires",{"count":53,"type":20},160,[23],"The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is:\n\nDoes primary RPLND lower the risk of side-effects compared to receiving chemotherapy?",[57,26,58,59,60],"Testicular Cancer","Quality of Life","De-escalation","RPLND",[62,28,63],"testicular cancer","primary RPLND","RECRUITING","2026-03-24",{"date":67,"type":36},"2026-03-27",{"date":69,"type":36},"2026-03-19",{"date":71,"type":20},"2032-03-25",{"name":73,"class":43},"Sahlgrenska University Hospital",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":74},"100539892","therapy-de-escalation-for-testicular-cancer-100539892","NCT06309745","THERApy De-escalation for TESTicular Cancer","THERATEST","Inclusion Criteria:\n\nEach patient must meet all of the following inclusion criteria to be enrolled in the study:\n\n1. Willing and able to provide written informed consent.\n2. Male.\n3. Age ≥ 16 years.\n4. Histologically confirmed seminoma (biopsy\u002Forchidectomy)\n5. Clinical stage II (standard of care cross-sectional imaging).\n6. Ability to comply with the protocol, including but not limited to, completion of the patient-reported outcome questionnaires.\n\nrRPLND cohort specific inclusion criteria\n\nParticipants must meet the following additional inclusion criteria to register for the rRPLND cohort:\n\n1. Stage IIA and \\\u003C3cm IIB with unifocal ipsilateral lymph node within rRPLND template.\n2. Negative or mildly elevated serum tumour markers, defined as:\n\n   1. AFP (alpha-fetoprotein) \\\u003C10ng\u002Fml and non-rising on serial testing\n   2. BhCG (human chorionic gonadotropin) \\\u003C50mg\u002Fml\n   3. LDH (lactate dehydrogenase) \\\u003C1.5x upper limit normal\n3. Fit for surgery, defined as meeting all of the following criteria:\n\n   1. Body mass index (BMI) \\\u003C34\n   2. Charlson comorbidity index ≤3\n   3. ECOG Performance status 0-1\n   4. No significant cardio-pulmonary disease, or other uncontrolled intercurrent illness that would limit fitness for surgery in the opinion of the investigator\n   5. No previous open intra-abdominal surgery\n\nCarboplatin AUC10 cohort specific inclusion criteria\n\nParticipants must meet the following additional inclusion criteria to register for the Carboplatin AUC10 group:\n\n1. Serum tumour markers, defined by IGCCCG \"good risk\" criteria:\n\n   1. AFP \\\u003C10ng\u002Fml\n   2. any BhCG\n   3. LDH \\\u003C2.5x ULN\n2. Glomerular filtration rate by EDTA clearance over 25 ml\u002Fmin (a measured creatinine clearance using Cockcroft and Gault would be allowed if unable to perform EDTA clearance).\n3. ECOG Performance status 0-2.\n4. Patients must be sterile or agree to use adequate contraception during the period of therapy.\n\nExclusion Criteria:\n\n1. Raised AFP \\> 10ng\u002Fml that does not fall to \\\u003C10ng\u002Fml following orchidectomy\n2. Previous chemotherapy or radiotherapy for the disease under study.\n3. Previous or concurrent malignancy other than testicular cancer, unless treated with curative intent and with no known active disease present for ≥2 years before enrolment and felt to be at low risk for recurrence by the treating physician (for example: non-melanoma skin cancer or lentigo maligna; breast ductal carcinoma in situ; prostatic intraepithelial neoplasia; urothelial papillary non-invasive carcinoma or urothelial carcinoma in situ).\n4. Any condition that, in the opinion of the investigator, would interfere with evaluation of study intervention or interpretation of patient safety or study results such as medical comorbidities impacting on QoL or medical conditions or other disorders that would affect adherence to study requirements","16 Years",{"count":84,"type":20},30,"OBSERVATIONAL","THERATEST is looking to collect data from 30 patients actively receiving de-escalation treatments or other standard of care treatments in two UK hospitals. THERATEST is a feasibility study to determine whether patients are willing to be recruited, the impact of de-escalation treatments on patients' cancers and quality of life, whether we should proceed with these treatments in a larger study, and if so how the study should be conducted. A feasibility study prepares the ground for a larger study and improves the chances of the subsequent study producing valuable evidence, and helps to avoid wasting precious resources on larger trials that are unlikely to be informative. We hope that information from THERATEST will bridge the current knowledge gap and allow clinicians to design bigger trials to actively compare the different treatment strategies.",[26],"2026-02-26",{"date":90,"type":36},"2026-03-02",{"date":92,"type":36},"2024-06-24",{"date":94,"type":20},"2028-10-02",{"name":96,"class":43},"Queen Mary University of London",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":74},"100526346","robot-assisted-icg-guided-sentinel-node-biopsy-in-testicular-cancer-100526346","NCT06133543","Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer","RAISN - Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer","RAISN","Inclusion Criteria:\n\n* Clinically confirmed unequivocal testicular tumor by palpation and sonography with or without elevation of specific tumor markers AFP and\u002For ß-HCG.\n* Clinical exclusion of metastases in preoperative staging using contrast-enhanced CT of the thorax and abdomen.\n* The patient is of legal age.\n* The patient can communicate with the investigator without issues or limitations and can understand and sign the patient information and consent form without problems or limitations.\n\nExclusion Criteria:\n\n* Testicular tumor with uncertain dignity\n* Patients with small testicular masses (\\\u003C 1 cm)\n* Patients with prior scrotal or retroperitoneal surgery for reasons other than a germ cell tumor.\n* The patient has received different chemotherapy.\n* The patient has undergone retroperitoneal radiotherapy.\n* Exclusion criteria for the use of ICG include a history of anaphylactic reactions to ICG and iodine intolerance (ICG solution contains sodium iodide).\n* The patient is in a reduced general condition or has a life-threatening illness.\n* The patient has a psychiatric illness.","99 Years",{"count":107,"type":20},44,[23],"Robot-assisted image-guided sentinel lymph node biopsy (RAISN) in testicular cancer is a novel technique that has not been widely investigated yet. This technique is promising and could be implemented as a future standard in the primary diagnostic work up of clinical stage (CS) I testicular cancer. Current staging strategies have a poor predictive accuracy for occult metastatic disease.\n\nSo far, feasibility studies used 99mTC-nanocolloid staining and laparoscopy and all patients with tumor-positive nodes received adjuvant systemic treatment. The development of a robot-assisted image-guided lymph node resection technique with indocyanine green (ICG) is potentially more precise, easier to apply and widely available. With this new diagnostic approach the management of newly diagnosed testicular cancer patients might be changed dramatically by reducing overtreatment and treatment-related toxicity with a minimally invasive robot-assisted procedure.",[111,26,112],"Germ Cell Tumor","Nonseminomatous Germ Cell Tumor","2025-09-09",{"date":115,"type":36},"2025-09-15",{"date":117,"type":36},"2023-09-06",{"date":119,"type":20},"2028-03-31",{"name":121,"class":43},"Heinrich-Heine University, Duesseldorf",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":129,"targetDuration":4,"studyType":21,"phases":131,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":74},"100527205","phase-2-primetest-ii---clinical-stage-ii-ab-seminoma-treated-with-ra-rplnd-100527205","NCT06144736","PRIMETEST II - Clinical Stage II A\u002FB Seminoma Treated With RA-RPLND","PRIMETEST II - Phase II Trial to Prospectively Test New Predictors for Recurrence in Patients With Clinical Stage II A\u002FB Seminoma Treated With RA-RPLND","Inclusion Criteria:\n\n* Histologically confirmed pure seminomatous testicular germ cell tumor\n* Presence of iliac or retroperitoneal lymph node metastasis detected in contrast-enhanced CT or MRI, classified as local or unilaterally regional\n* Maximum extent of lymph node metastasis (LN-M) singular or multiple, with a maximum size of 5 cm in transverse CT diameter (UICC IIB)\n* Patients with an elevation in HCG after orchiectomy at the time of staging examination can be included if the directly preoperatively determined HCG does not exceed 5 IU\u002FL.\n\nPatients can be included in the following scenarios:\n\n* Initial diagnosis of a tumor in UICC stage IIA\u002FIIB\n* Recurrence of a tumor in clinical stage (CS) I under active surveillance\n* Recurrence of a CS I tumor after adjuvant therapy with carboplatin mono\n\nExclusion Criteria:\n\n* LN-M with a transverse diameter \\>5 cm in CT (UICC IIC)\n* Other metastases than LN-M (UICC III)\n* The patient received a different chemotherapy than described above\n* The patient underwent retroperitoneal radiotherapy\n* The patient is in a reduced general condition or has a life-threatening illness\n* The patient has a psychiatric illness\n* Evidence of non-seminomatous germ cell tumor components in the RPLND histology\n* Complete resection cannot be ensured due to previous surgeries\n* In the \"high risk\" group: Contraindications to cisplatin, etoposide, or bleomycin (severe liver insufficiency, severe kidney insufficiency, severe lung insufficiency, hypersensitivity, severe bone marrow depression, profound hearing impairments)",{"count":130,"type":20},60,[132],"PHASE2","PRIMETEST II is an interventional study involving low-volume metastatic seminoma. It explores a novel approach using robot-assisted primary retroperitoneal lymph node dissection, aiming to reduce long-term side effects and improve quality of life. By identifying factors predicting cancer recurrence, the study hopes to tailor treatments for better outcomes. The approach could potentially spare patients from chemotherapy induced long-term side effects while maintaining excellent survival rates, presenting a promising shift in testicular cancer care for this specific patient group.",[26],[28,136,137],"low volume metastases","clinical stage IIA\u002FB",{"date":115,"type":36},{"date":140,"type":36},"2023-08-28",{"date":142,"type":20},"2029-08-31",{"name":121,"class":43},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":21,"phases":154,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100450245","radiotherapy-vs-observation-for-post-chemotherapy-residual-mass-in-advanced-seminoma-100450245","NCT05142982","Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma","FDG PET-CT Based Risk Adapted Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma: A Prospective Randomised Controlled Trial","Inclusion Criteria:\n\n1. Histological diagnosis of classical seminoma\n2. Primary site - testis, mediastinum or retroperitoneum\n3. Stage IIB-IIIC (AJCC 8th edition)\n4. Age\\>18 years\n5. Karnofsky Performance Status at least 70\n6. A response assessment FDG PETCT scan done at least twelve weeks after the first line chemotherapy, showing a persistent measurable residual mass\n7. Patient willing and reliable for follow up and QOL.\n\nExclusion Criteria:\n\n1. Histology other than classical seminoma\n2. Non completion of planned first-line chemotherapy\n3. Prior history of radiotherapy to the involved region\n4. Inability to deliver adequate radiotherapy dose safely based on assessment by radiation oncologist","80 Years",{"count":153,"type":20},74,[23],"Testicular tumors account for 1% of all cancers in males and germ cell tumors comprise 95% of all testicular cancers. Seminomas consist of around 50% of cases. However,adequate information is not there as 60- 80% residual disease is seen even after with the standard management of chemotherapy.\n\nWith the advent of functional imaging there was hope that it could aid in more accurately targeting these tumors to systematically evaluate the role of PET-CT imaging in identifying patients diagnosed with stage IIB-IIIC seminomatous germ cell tumor, with residual visible tumor post chemotherapy who would benefit with loco regional radiotherapy.\n\nThe therapeutic research in Seminomashas been relatively slow and such structured studies can allow analysis of large number of patients to report on acute and late effect of treatment outcomes using CTCAE and QOL (EORTC QLQ C-30) in these cancers. We hope that we will get help in identifying thrust areas for future research through this study.",[26],[158],"FDG-PET CT, radiotherapy","2025-02-07",{"date":161,"type":36},"2025-02-11",{"date":163,"type":36},"2021-12-01",{"date":165,"type":20},"2029-12-15",{"name":167,"class":43},"Tata Memorial Centre",2,{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":21,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":206},"100479920","phase-2-de-escalation-study-for-stage-iiaiib--3-cm-seminoma-100479920","NCT05529251","De-escalation Study for Stage IIa\u002FIIb \u003C 3 cm Seminoma","Prospective Therapeutic De-escalation and miRNA-M371 Biomarker Evaluation Phase II Study for Stage IIa\u002FIIb \u003C 3 cm Seminomas","EDEN","Inclusion criteria :\n\n1. Age ≥ 18 years on the day of signing informed consent.\n2. Primary testicular seminomatous germ cell tumor.\n3. Stage IIa\u002FIIb \\\u003C 3 cm in largest diameter seminoma, histologically proved after orchiectomy.\n4. Confirmation of a progressive disease (positive PET scan or increase of lymph nodes size by two successive CT scan).\n5. Good prognosis according to IGCCCG and LDH \\\u003C 2.5 x Upper Limit of Normal (ULN).\n6. Normal alpha-fetoprotein (AFP) before and after orchiectomy.\n7. No prior treatment with radiotherapy or chemotherapy.\n8. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2.\n9. Adequate bone-marrow, hepatic, and renal functions with:\n\n   * Neutrophils ≥ 1.5 x Giga\u002Fl, platelets ≥ 100 x Giga\u002Fl,\n   * Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 1,5 x ULN,\n   * Serum creatinine \\\u003C 140 µmol\u002Fl OR calculated clearance \\> 60 ml\u002Fmin (using either Cockcroft-Gault formula or Modification of Diet in Renal Disease (MDRD) for \\> 65 years old),\n   * Direct and total bilirubin ≤ ULN.\n10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.\n11. Accepting to use effective contraceptive measures or abstain from heterosexual activity, for the course of the study and through 12 months after the last dose of chemotherapy or being surgically sterile. All patients should seek advice regarding cryoconservation of sperm prior treatment initiation because of the possibility of infertility\n12. Affiliation to a health insurance.\n13. Signed and dated informed consent.\n\nNon-exclusion criteria :\n\n1. Extra-retroperitoneal metastasis on Computed tomography scan (CT scan).\n2. Infection by Human Immunodeficiency Virus (HIV), or active infection with the Hepatitis B or C virus.\n3. History, within 2 years, of cancer other than seminoma, except for treated skin cancer (basal cell).\n4. Uncontrolled or severe cardiovascular pathology.\n5. Uncontrolled or severe hepatic pathology.\n6. Patient deprived of liberty or requiring tutorship or curatorship.\n7. Psychological, physical, sociological, or geographical conditions that would limit compliance with study protocol requirements (at the investigator's discretion).\n8. Participation to another clinical trial, except for supportive care trials.",{"count":178,"type":20},90,[132],"Phase II, multicenter, prospective, randomized, non-comparative, de-escalation study.\n\nPatients with stage IIa\u002FIIb \\\u003C 3 cm seminoma histologically proved after orchiectomy will be included in the study and will receive 1 cycle of Etoposide Cisplatine (EP) chemotherapy.\n\nPatients with negative week-3 PET-scan after the EP cycle, will be randomized (1:1 ratio, stratification according to the disease stage (stage IIa versus IIb seminoma)) to receive either radiotherapy (RT) boost on lymph nodes or 1 cycle of carboplatin AUC7 chemotherapy.\n\nPatients with positive week-3 PET-scan will received 3 additional cycles of EP chemotherapy.\n\nIn parallel, eligible patients scheduled to receive standard lombo-aortic RT will be registered in an observational cohort.",[26,182],"Stage II",[59,184,185,186,187,188,189,190,191,192,193,194,195,196],"Chemotherapy","Radiotherapy","Carboplatin","Etoposide","Cisplatine","Micro-RNA-M371","PET scan","Overall survival","Biomarker","Efficacy","Progression free rate","Safety","Quality of life","2024-01-24",{"date":199,"type":36},"2024-01-25",{"date":201,"type":36},"2022-09-06",{"date":203,"type":20},"2030-09-06",{"name":205,"class":43},"Centre Leon Berard",15,{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":235},"100432662","microrna-as-markers-in-testicular-cancer-100432662","NCT04914026","MicroRNA as Markers in Testicular Cancer","MicroRNA-371 as Markers for Disease Activity and as a Tool to Monitor the Effect of Chemotherapy and Early Detection of Recurrence in Patients With Testicular Germ Cell Tumours","Inclusion Criteria:\n\n* Patients with suspected testicular cancer, referred to orchiectomy.\n* Patients diagnosed with testicular germ cell cancer.\n* Age 18-70 years of age.\n* Must be able receive information and to consent.\n\nExclusion Criteria:\n\n* Other prior or concomitant malignancy (other than testicular cancer).\n* Other diseases or conditions that hinder the ability to receive information and to participate in follow-up procedures.","70 Years",{"count":216,"type":20},350,"The main objective of this study is establish the performance of miR371 in management of testicular cancer",[219,26,220,221,222,223,224,225],"Testicular Germ Cell Cancer","Non-Seminoma Testicular Cancer","Stage I Testicular Cancer","Stage II Testicular Cancer","Stage III Testicular Cancer","Stage IV Testicular Cancer","Relapse Testicular Cancer","2022-08-05",{"date":228,"type":36},"2022-08-08",{"date":230,"type":36},"2016-12-31",{"date":232,"type":20},"2026-12-31",{"name":234,"class":43},"Haukeland University Hospital",6,{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":21,"phases":246,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":74},"100200576","phase-2-therapeutic-strategy-guided-by-pet-tdm-for-patients-with-seminoma-100200576","NCT01887340","Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma","Therapeutic Strategy Guided by PET-TDM for Patients With Grade I or Metastatic Seminoma","SEMITEP","Inclusion Criteria shared:\n\n* Histologically proved seminoma after orchiectomy\n* Primary testicular or retroperitoneal\n* Normal alpha-fetoprotein before and after orchiectomy\n* No prior treatment with radiotherapy or chemotherapy\n* Age \\>= 18 years\n* ECOG 0 to 2\n* PNN \\>= 1500, platelets \\>= 100 000, bilirubin \\\u003C= the upper limit nromale\n* ASAT (SGOT) and ALAT (SGPT) \\\u003C= 1,5 x the upper limit nromale\n* Serum creatinine \\\u003C140 µmol \u002F L (or clearance\\> 60 mL \u002F min)\n* Information and signed informed consent before inclusion in the study\n* Patient affiliated to a social security\n\nSpecific inclusion criteria for cohort 1:\n\n* grade I\n\nSpecific inclusion criteria for cohort 2:\n\n* grade IIB (retroperitoneal adenopathy diameter between 2 cm and 5 cm, regardless of the LDH)\n* grade IIC (retroperitoneal adenopathy diameter higher than 5 cm, regardless of the LDH)\n* grade III of good prognosis (supradiaphragmatic reach with ganglionic metastasis and LDH \\\u003C 2 times normal limit and\u002For supradiaphragmatic reach with pulmonary metastasis and LDH \\\u003C 2 times normal limit) either at initial diagnosis or relapse of a grade I seminoma)\n* PET-TDM positive (pathological fixation on metastatic lesions)\n\nExclusion Criteria shared:\n\n* Patient infected by HIV, Hepatitis B or C\n* History, within 5 years, of cancer other than seminoma, except for treated skin cancer (Basal Cell) .\n* visceral metastasis\n* cerebral metastasis\n* Any physical or mental condition incompatible with the treatment (to the investigator discretion)\n* Uncontrolled or severe cardiovascular pathology\n* Uncontrolled or severe hepatic pathology\n* Persons deprived of liberty or under guardianship\n* Unable to undergo medical monitoring due to geographical, social or psychological reasons",{"count":245,"type":20},271,[132],"The purpose of the study is to evaluate the ration of patients getting an lighten therapeutic strategy after 18F-fluoro-désoxyglucose positron emission tomography (PET-TDM) in grade I (cohort 1) or metastatic (cohort 2) seminoma",[26],"2016-06-08",{"date":251,"type":20},"2016-06-09",{"date":253,"type":4},"2013-06",{"date":255,"type":20},"2026-06",{"name":257,"class":43},"Gustave Roussy, Cancer Campus, Grand Paris"]